Trials / Not Yet Recruiting
Not Yet RecruitingNCT07244874
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
A Single Arm, Phase II Study of Sacituzumab Tirumotecan（Sac-TMT） Combined With Toripalimab for First-line Treatment of PD-L1 Positive Unresectable Locally Advanced/Metastatic Triple Negative Breast Cancer (a/mTNBC)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is aimed to evaluate the efficacy and safety of Sacituzumab Tirumotecan combined with Toripalimab for first-line treatment of PD-L1 positive unresectable Locally Advanced/metastatic triple negative breast cancer (a/mTNBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacituzumab tirumotecan | 5mg/kg, Q2W |
| DRUG | Toripalimab | 240mg，Q3W |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2028-01-30
- Completion
- 2029-07-30
- First posted
- 2025-11-24
- Last updated
- 2025-11-24
Source: ClinicalTrials.gov record NCT07244874. Inclusion in this directory is not an endorsement.